CU Logo University of Colorado Anschutz Medical Campus
Back to Results

A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects with Ovarian Cancer (NXP800-101; ENGOTGYN5/ NCRI/NXP800-101; GOG-3087)

Primary Objective

The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.

Is This Study For You?

Let's Get Started!

Description

Part A of the study is a dose escalation by cohort study of NXP800 administered to patients with advanced cancers. The study will identify the maximum tolerated dose (MTD) and propose dose and dose schedules for future studies. In Part B doses selected in Part A are administered to patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.

Details
Age
Adult
Eligibility
Detailed eligibility criteria is available on clinicaltrials.gov. These requirements will be discussed with your doctor and/or study representative. Click the NCT number link below to learn more about this study on ClinicalTrials.gov
Locations

CTRC Inpatient
University of Colorado Hospital

Principal Investigator
Photograph of Lindsay Brubaker

Lindsay Brubaker

Study ID

Protocol Number: 23-0966

More information available at ClinicalTrials.gov: NCT05226507

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers